MedTrace Logo

Assessment of the Therapeutic Utility of hMG-HP

NCT01330784 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 61

Last updated 2011-04-07

No results posted yet for this study

Summary

To assess the effectiveness of a protocol of ovarian hyperstimulation with urinary gonadotrophins, to achieve clinical pregnancy in females undergoing IVF.

Study hypothesis: to assess the effectiveness of a protocol of urinary gonadotrophins

Conditions

  • Sterility

Interventions

DRUG

hMG-HP

Sponsors & Collaborators

  • Ferring SAU

    collaborator INDUSTRY

  • Ferring Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Clinical Development Support · Ferring Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
38 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2008-07-31
Completion
2008-09-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01330784 on ClinicalTrials.gov